BRL 50481 - CAS 433695-36-4
Catalog number: 433695-36-4
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C9H12N2O4S
Molecular Weight:
244.27
COA:
Inquire
Targets:
Phosphodiesterase (PDE)
Description:
BRL 50481 is a potent, selective substrate-competitive inhibitor of phosphodiesterase (PDE) 7 (Ki = 180 nM).
Purity:
≥95%
Appearance:
Off-White Solid
Synonyms:
BRL-50481; BRL 50481; BRL50481. 3-(N,N-Dimethylsulfonamido)-4-methylnitrobenzene, 5-Nitro-2-N,N-trimethylbenzenesulfonamide;
Solubility:
Soluble in DMSO
Storage:
Store at -20 °C
MSDS:
Inquire
Application:
A PDE7 inhibitor that has acceptable selectivity for in vivo studies.
Quality Standard:
Enterprise standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.
Quantity:
Milligrams-Grams
Melting Point:
72-74 °C
InChIKey:
IFIUFCJFLGCQPH-UHFFFAOYSA-N
InChI:
1S/C9H12N2O4S/c1-7-4-5-8(11(12)13)6-9(7)16(14,15)10(2)3/h4-6H,1-3H3
Canonical SMILES:
CC1=C(S(N(C)C)(=O)=O)C=C([N+]([O-])=O)C=C1
1.Characterization of renal ecto-phosphodiesterase.
Jackson EK;Ren J;Zacharia LC;Mi Z J Pharmacol Exp Ther. 2007 May;321(2):810-5. Epub 2007 Feb 16.
In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to adenosine by ecto-5'-nucleotidase. Although much is known about ecto-5'-nucleotidase, the renal ecto-phosphodiesterase remains uncharacterized. We administered cAMP (10 microM in the perfusate) to 12 different groups of perfused kidneys. AMP was measured in perfusate using ion trap mass spectrometry. In control kidneys (n=19), basal renal secretion rate of AMP was 0.49+/-0.08 and increased to 3.0+/-0.2 nmol AMP/g kidney weight/min during administration of cAMP. A broad-spectrum phosphodiesterase (PDE) inhibitor (1,3-isobutyl-1-methylxanthine, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively. Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.
2.β-Adrenergic cAMP signals are predominantly regulated by phosphodiesterase type 4 in cultured adult rat aortic smooth muscle cells.
Zhai K;Hubert F;Nicolas V;Ji G;Fischmeister R;Leblais V PLoS One. 2012;7(10):e47826. doi: 10.1371/journal.pone.0047826. Epub 2012 Oct 18.
BACKGROUND: ;We investigated the role of cyclic nucleotide phosphodiesterases (PDEs) in the spatiotemporal control of intracellular cAMP concentrations in rat aortic smooth muscle cells (RASMCs).;METHODOLOGY/PRINCIPAL FINDINGS: ;The rank order of PDE families contributing to global cAMP-PDE activity was PDE4> PDE3  =  PDE1. PDE7 mRNA expression but not activity was confirmed. The Fluorescence Resonance Energy Transfer (FRET)-based cAMP sensor, Epac1-camps, was used to monitor the time course of cytosolic cAMP changes. A pulse application of the β-adrenoceptor (β-AR) agonist isoproterenol (Iso) induced a transient FRET signal. Both β(1)- and β(2)-AR antagonists decreased the signal amplitude without affecting its kinetics. The non-selective PDE inhibitor (IBMX) dramatically increased the amplitude and delayed the recovery phase of Iso response, in agreement with a role of PDEs in degrading cAMP produced by Iso. Whereas PDE1, PDE3 and PDE7 blockades [with MIMX, cilostamide (Cil) and BRL 50481 (BRL), respectively] had no or minor effect on Iso response, PDE4 inhibition [with Ro-20-1724 (Ro)] strongly increased its amplitude and delayed its recovery. When Ro was applied concomitantly with MIMX or Cil (but not with BRL), the Iso response was drastically further prolonged.
3.A novel PDE2A reporter cell line: characterization of the cellular activity of PDE inhibitors.
Wunder F;Gnoth MJ;Geerts A;Barufe D Mol Pharm. 2009 Jan-Feb;6(1):326-36. doi: 10.1021/mp800127n.
We report here the generation and pharmacological characterization of a phosphodiesterase 2A (PDE2A) reporter cell line. Human PDE2A was stably transfected in a parental cell line expressing the atrial natriuretic peptide (ANP) receptor and the cyclic nucleotide-gated (CNG) cation channel CNGA2, acting as the biosensor for intracellular cGMP. In this reporter cell line, cGMP levels can be monitored in real-time via aequorin luminescence stimulated by calcium influx through the CNG channel. By using different PDE inhibitors, we could show that our PDE2A reporter assay specifically monitors PDE2A inhibition with high sensitivity. In the absence of ANP stimulation, the PDE2A selective inhibitors EHNA, BAY 60-7550 and PDP did not increase basal luminescence levels in this experimental setting. However, in combination with ANP, these inhibitors stimulated luminescence signals and induced leftward shifts of ANP concentration-response curves. Similar results were obtained when using IBMX, trequinsin and dipyridamole, which inhibit PDE2A nonselectively with lower potency. PDP, the most potent PDE2A inhibitor known to date, was found to exhibit much lower cellular activity as anticipated from its biochemical PDE2A inhibitory activity.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Phosphodiesterase (PDE) Products


CAS 1082743-70-1 PDE-9 inhibitor

PDE-9 inhibitor
(CAS: 1082743-70-1)

PDE-9 inhibitor is useful for neurodegenerative diseases.

CAS 152815-28-6 RS 25344 hydrochloride

RS 25344 hydrochloride
(CAS: 152815-28-6)

RS 25344 hydrochloride is a potent and selective inhibitor of four cloned isoforms of PDE4 (A, B, C and D) and phosphorylated PDE4D (IC50= 0.28, > 100, 160 and ...

CAS 439083-90-6 Bay 60-7550

Bay 60-7550
(CAS: 439083-90-6)

Bay 60-7550 is a potent PDE2 inhibitor. It is 50-fold more selective for PDE2 compared to PDE1 and greater than 100-fold selective compared to PDE5 PDE3B, PDE4B...

CAS 78415-72-2 Milrinone

Milrinone
(CAS: 78415-72-2)

Milrinone is a phosphodiesterase 3 (PDE3) inhibitor with vasodilator properties, used to increase the heart's contractility. It increases erythrocyte cAMP activ...

ITI214
(CAS: 1642303-38-5)

ITI214 is a highly selective PDE1 inhibitor (Ki = 58 pM) at picomolar concentration without disrupting other PDE family members and a panel of enzymes, receptor...

CAS 1904611-63-7 PDE1-IN-2

PDE1-IN-2
(CAS: 1904611-63-7)

PDE1-IN-2 is an inhibitor of PDE1 that has IC50 values of 6, 140 and 164 nM for PDE1C, PDE1B and PDE1A, respectvely.

CAS 1236858-52-8 PF 04449613

PF 04449613
(CAS: 1236858-52-8)

PF 04449613 is a potent PDE9 inhibitor (IC50 = 22 nM), and also shows a high affinity for cGMP (Km ~170 nM). Some studies suggest that elevating the level of cG...

CAS 6493-05-6 Pentoxifylline

Pentoxifylline
(CAS: 6493-05-6)

Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis,...

Quick Inquiry

Verification code

Featured Items